Shuttle Pharmaceuticals Holdings Inc SHPH

NAS: SHPH | ISIN: US8256932034 7/05/2024

0,417 USD (+3,47%)

(+3,47%) 7/05/2024

Grafiek Shuttle Pharmaceuticals Holdings Inc

Grafiek Shuttle Pharmaceuticals Holdings Inc

1 dag1d 3,47%
1 week1w 2,43%
1 maand1m -0,74%
3 maanden3m 10,99%
6 maanden6m -16,48%
1 jaar1j -67,93%
5 jaar5j -98,92%

Shuttle Pharmaceuticals Holdings Inc in het nieuws

Toon enkel gratis nieuws

22 maart 2024 · Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update · Persbericht

13 februari 2024 · Shuttle Pharma Announces Its Intent to Pursue a Rights Offering · Persbericht

23 januari 2024 · Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 · Persbericht

8 januari 2024 · Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma · Persbericht

11 december 2023 · Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma · Persbericht

31 oktober 2023 · Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement · Persbericht

10 oktober 2023 · Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference · Persbericht

25 september 2023 · Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma · Persbericht

13 september 2023 · Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men's Health Fair · Persbericht

11 september 2023 · Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform · Persbericht

Profiel Shuttle Pharmaceuticals Holdings Inc

Werknemers: 5

Aandelen Shuttle Pharmaceuticals Holdings Inc

Beurswaarde: 6,77 miljoen USD

Effecten: 16,79 miljoen

Beta: 0,17

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe